CLASS ACTION UPDATE for SOGO, PRGO, AGN and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Feb. 13, 2019 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Sogou Inc. (NYSE: SOGO)
Class Period: Purchasers of American Depositary Shares pursuant and/or traceable to Sogou’s false and misleading Registration Statement and Prospectus issued in connection with the Company’s initial public offering on November 9, 2017
Lead Plaintiff Deadline: March 11, 2019
Join the action: https://www.zlk.com/pslra-1/sogou-inc-loss-form?wire=3

About the lawsuit: During the class period, Sogou Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Chinese regulators were analyzing Sogou for regulatory action because of an increase in Sogou merchants’ sales of counterfeit goods; (ii) Chinese regulators were analyzing Sogou for regulatory action because Sogou’s existing software, advertising  procedures, personnel, and audit procedures were insufficient to safeguard against compliance violations with governing Chinese  regulations, and would need to be updated, enhanced, and strengthened, thus resulting in increased expenses; (iii) Sogou’s cost of revenues were skyrocketing primarily because of significant increases in Traffic Acquisition Cost, which is a primary driver of Sogou’s cost of revenues, as Sogou was dealing with significant price inflation from increased competition; (iv) Sogou was going to alter its strategy concerning smart hardware and push the Company’s AI capabilities to increase product competitiveness; (v) as a result of altering  its smart  hardware  strategy,  Sogou had already decided to phase out non-AI-enabled hardware products, such as legacy models of Teemo Smart Watch, and transition to use products integrating AI technologies, which Sogou hoped would reduce its hardware  revenue  in the second half of  2018; and (vi) as a result of the foregoing, Sogou’s  public statements were materially false and misleading at all relevant times.

To learn more about the Sogou Inc. class action contact [email protected].

Perrigo Company plc (NYSE: PRGO)
Class Period: November 8, 2018 – December 20, 2018
Lead Plaintiff Deadline: March 4, 2019
Join the action: https://www.zlk.com/pslra-1/perrigo-company-plc-loss-form?wire=3

During the Class Period, and unbeknownst to investors, Perrigo misled investors by way of an SEC filing on November 8, 2018. On that date, Perrigo disclosed the existence of an audit finding letter from the Irish tax authorities without disclosing material details associated with the letter.

To learn more about the Perrigo Company plc class action contact [email protected].

Allergan plc (NYSE: AGN)
Class Period: February 24, 2017 – December 19, 2018
Lead Plaintiff Deadline: February 19, 2019
Join the action: https://www.zlk.com/pslra-1/allergan-plc-loss-form?wire=3

About the lawsuit: Allergan plc allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) textured breast implants manufactured by Allergan were linked to ALCL; (ii) the foregoing link to cancer, when revealed, would foreseeably force Allergan to recall those textured breast implants from the market; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Allergan plc class action contact [email protected].

Alkermes plc (NASDAQGS: ALKS)
Class Period: February 17, 2017 – November 1, 2018
Lead Plaintiff Deadline: February 25, 2019
Join the action: https://www.zlk.com/pslra-1/alkermes-plc-loss-form?wire=3

About the lawsuit: During the class period, Alkermes plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for its drug ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

To learn more about the Alkermes plc class action contact [email protected].

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com